177 related articles for article (PubMed ID: 33014823)
1. Effective Treatment With Afatinib of Lung Adenocarcinoma With Leptomeningeal Metastasis Harboring the Exon 18 p.G719A Mutation in the EGFR Gene Was Detected in Cerebrospinal Fluid: A Case Report.
Ma C; Wang S; Mu N; Li J; Liu M; Li L; Jiang R
Front Oncol; 2020; 10():1635. PubMed ID: 33014823
[No Abstract] [Full Text] [Related]
2. Afatinib for Advanced Non-small Cell Lung Cancer in a Case With an Uncommon Epidermal Growth Factor Receptor Mutation (G719A) Identified in the Cerebrospinal Fluid.
Ma C; Huang C; Tang D; Ye X; Li Z; Liu R; Mu N; Li J; Jiang R; Zhang J
Front Oncol; 2019; 9():628. PubMed ID: 31396478
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of afatinib for pulmonary adenocarcinoma with leptomeningeal metastases harboring an epidermal growth factor receptor complex mutation (exon 19del+K754E): A case report.
Ma C; Liu M; Mu N; Li J; Li L; Jiang R
Medicine (Baltimore); 2020 Oct; 99(43):e22851. PubMed ID: 33120820
[TBL] [Abstract][Full Text] [Related]
4. Cerebrospinal Fluid Penetration Rate and Efficacy of Afatinib in Patients with EGFR Mutation-positive Non-small Cell Lung Cancer with Leptomeningeal Carcinomatosis: A Multicenter Prospective Study.
Tamiya A; Tamiya M; Nishihara T; Shiroyama T; Nakao K; Tsuji T; Takeuchi N; Isa SI; Omachi N; Okamoto N; Suzuki H; Okishio K; Iwazaki A; Imai K; Hirashima T; Atagi S
Anticancer Res; 2017 Aug; 37(8):4177-4182. PubMed ID: 28739703
[TBL] [Abstract][Full Text] [Related]
5. EGFR (p. G719A+L747V)/EML4-ALK Co-alterations in Lung Adenocarcinoma with Leptomeningeal Metastasis Responding to Afatinib Treatment: A Case Report.
Lu Z; Wang X; Luo Y; Wei J; Zeng Z; Xiong Q; Cai J; Liu A
Onco Targets Ther; 2021; 14():2823-2828. PubMed ID: 33935502
[TBL] [Abstract][Full Text] [Related]
6. Erlotinib and bevacizumab combination therapy for afatinib-refractory leptomeningeal carcinomatosis from EGFR-mutated lung cancer.
Abe M; Osoegawa A; Karashima T; Takumi Y; Kobayashi R; Hashimoto T; Miyawaki M; Takeuchi H; Okamoto T; Sugio K
Int Cancer Conf J; 2019 Apr; 8(2):81-85. PubMed ID: 31149553
[TBL] [Abstract][Full Text] [Related]
7. Epidermal Growth Factor Receptor Mutation Detection in Cerebrospinal Fluid of Lung Adenocarcinoma Patients with Leptomeningeal Metastasis.
Huang R; Ge M; Zhou X; Ji X; Liao L; Liang X; Zhan Q
Cancer Biother Radiopharm; 2019 Mar; 34(2):128-133. PubMed ID: 30452286
[TBL] [Abstract][Full Text] [Related]
8. Different next-generation sequencing pipelines based detection of tumor DNA in cerebrospinal fluid of lung adenocarcinoma cancer patients with leptomeningeal metastases.
Ge M; Zhan Q; Zhang Z; Ji X; Zhou X; Huang R; Liang X
BMC Cancer; 2019 Feb; 19(1):143. PubMed ID: 30755180
[TBL] [Abstract][Full Text] [Related]
9. Clinical Efficacy of Afatinib Treatment for a Patient with Leptomeningeal Carcinomatosis.
Kawaguchi Y; Hanaoka J; Hayashi H; Mizusaki N; Iihara H; Itoh Y; Sugiyama T
Chemotherapy; 2017; 62(3):147-150. PubMed ID: 28030859
[TBL] [Abstract][Full Text] [Related]
10. Comparing the effects of afatinib with gefitinib or Erlotinib in patients with advanced-stage lung adenocarcinoma harboring non-classical epidermal growth factor receptor mutations.
Shen YC; Tseng GC; Tu CY; Chen WC; Liao WC; Chen WC; Li CH; Chen HJ; Hsia TC
Lung Cancer; 2017 Aug; 110():56-62. PubMed ID: 28676220
[TBL] [Abstract][Full Text] [Related]
11. Afatinib successfully treated leptomeningeal metastasis during erlotinib treatment in a patient with EGFR-mutant (Exon18:G719S) lung adenocarcinoma as a second-line chemotherapy.
Tamiya M; Shiroyama T; Nishihara T; Nishida T; Hayama M; Tanaka A; Morishita N; Suzuki H; Okamoto N; Hirashima T
Asia Pac J Clin Oncol; 2017 Oct; 13(5):e531-e533. PubMed ID: 28004883
[TBL] [Abstract][Full Text] [Related]
12. EGFR exon 18 delE709_T710insD mutated stage IV lung adenocarcinoma with response to afatinib.
Ibrahim U; Saqib A; Atallah JP
Lung Cancer; 2017 Jun; 108():45-47. PubMed ID: 28625646
[TBL] [Abstract][Full Text] [Related]
13. Promising Effects of Afatinib on Leptomeningeal Carcinomatosis Derived from Erlotinib-resistant Lung Adenocarcinoma.
Sekine A; Kato T; Iwasawa T; Baba T; Suido A; Sakuranaka H; Futaki M; Ogura T
Intern Med; 2016; 55(17):2457-61. PubMed ID: 27580550
[TBL] [Abstract][Full Text] [Related]
14. Tyrosine Kinase Inhibitors Could Be Effective Against Non-small Cell Lung Cancer Brain Metastases Harboring Uncommon
Ma C; Zhang J; Tang D; Ye X; Li J; Mu N; Li Z; Liu R; Xiang L; Huang C; Jiang R
Front Oncol; 2020; 10():224. PubMed ID: 32195178
[No Abstract] [Full Text] [Related]
15. Response to afatinib in treatment-naïve patients with advanced mutant epidermal growth factor receptor lung adenocarcinoma with brain metastases.
Li SH; Liu CY; Hsu PC; Fang YF; Wang CC; Kao KC; Tseng LC; Yang CT
Expert Rev Anticancer Ther; 2018 Jan; 18(1):81-89. PubMed ID: 29172778
[TBL] [Abstract][Full Text] [Related]
16. Corrigendum: Afatinib for Advanced Non-small Cell Lung Cancer in a Case With an Uncommon Epidermal Growth Factor Receptor Mutation (G719A) Identified in the Cerebrospinal Fluid.
Ma C; Huang C; Tang D; Ye X; Li Z; Liu R; Mu N; Li J; Jiang R; Zhang J
Front Oncol; 2019; 9():938. PubMed ID: 31641649
[TBL] [Abstract][Full Text] [Related]
17. EGFR Exon 18 Mutations in Lung Cancer: Molecular Predictors of Augmented Sensitivity to Afatinib or Neratinib as Compared with First- or Third-Generation TKIs.
Kobayashi Y; Togashi Y; Yatabe Y; Mizuuchi H; Jangchul P; Kondo C; Shimoji M; Sato K; Suda K; Tomizawa K; Takemoto T; Hida T; Nishio K; Mitsudomi T
Clin Cancer Res; 2015 Dec; 21(23):5305-13. PubMed ID: 26206867
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of multimodal treatment for leptomeningeal metastases in a lung cancer harboring an EGFR mutation.
Morichika D; Kubo T; Gotoda H; Tamura T; Ohashi K; Hotta K; Tabata M; Kurozumi K; Tanimoto M; Kiura K
Onco Targets Ther; 2016; 9():1753-8. PubMed ID: 27042125
[TBL] [Abstract][Full Text] [Related]
19. The clinical efficacy of Afatinib 30 mg daily as starting dose may not be inferior to Afatinib 40 mg daily in patients with stage IV lung Adenocarcinoma harboring exon 19 or exon 21 mutations.
Yang CJ; Tsai MJ; Hung JY; Lee MH; Tsai YM; Tsai YC; Hsu JF; Liu TC; Huang MS; Chong IW
BMC Pharmacol Toxicol; 2017 Dec; 18(1):82. PubMed ID: 29237484
[TBL] [Abstract][Full Text] [Related]
20. Early detection of circulating tumor DNA and successful treatment with osimertinib in thr790met-positive leptomeningeal metastatic lung cancer: A case report.
Xu LQ; Wang YJ; Shen SL; Wu Y; Duan HZ
World J Clin Cases; 2022 Aug; 10(22):7968-7972. PubMed ID: 36158482
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
